Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
about
Patient-derived tumour xenografts as models for oncology drug developmentEGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibResistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategiesMolecular pathology of lung cancer: key to personalized medicine.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceA novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activationA comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.The quest to overcome resistance to EGFR-targeted therapies in cancer.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model systemMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapyTyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cellsThird-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell linesRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.Tyrosine kinase inhibitors in lung cancer.Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.The two faces of FBW7 in cancer drug resistance.Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancerErlotinib resistance in lung cancer: current progress and future perspectives.Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Drug Resistance to EGFR Inhibitors in Lung CancerMechanisms of resistance to EGFR targeted therapies.
P2860
Q54908037-2388A22D-1292-408C-8FAE-07D74C6CDCBCQ54938481-AAF58DA9-F915-4C4B-8B6A-574122AA4597Q54938482-6BC228C1-9142-4556-9550-30989B8FC3E7Q54938483-E4933CDD-41BF-4F38-8625-7AD5C8C6701FQ54938484-A15D49C5-8024-4530-BC4D-A411C7541359Q54938485-A0D41091-BEA9-458E-BCDA-A746481DEC03Q54938486-8365BCF5-916D-43B9-9362-AB75182A359BQ54938494-18B400B1-7509-4C49-B58A-6AF2B34B20BAQ54938495-5F59A735-D64D-4762-8BA0-90CC0C65CFE6Q54938496-E4756660-1B4D-450D-BD1E-6347ED6BBF43Q54938497-C63983EC-BC0C-4E02-B66A-CF8E6B2E8CEEQ54938498-38AEB9B5-1B44-4C9D-A65F-3AC667B75937Q54938499-70E51CA3-A192-4002-8F95-F3FBDD9D18F3
P1343
Q24604068-665AAC53-D8AE-42B2-8CFB-BC2862974222Q24606177-9C5CF77F-ADB8-4CF1-A5E6-DE2F1B86C1FBQ27004161-DEC204D2-B625-452E-BE18-A85FD60EFCA9Q27691299-4C37288E-216B-4E9E-A45F-F30412F00620Q27851628-34C99329-FA2A-4D2D-A0BD-CA6348FA5430Q27851633-272FC1E0-F197-4273-98F3-4A9F3AC5ED9BQ27851660-4F2B0839-FC33-4C94-A4DF-D54F0FC29FEDQ27851896-A6C13F52-7FE1-43A5-AF93-6F421231866EQ28079320-3D418EA2-7C26-4DE6-AD96-95DA20C196FEQ28480605-70E9E2D6-3391-4EEB-913B-73F59EB2A9D7Q33605906-4DFB87FF-6CCA-4589-AD1A-5FBCBF5549B9Q33725972-377839F1-98CF-4D5C-A89F-858600E5C75FQ33725976-30673F08-2A08-4C49-B019-CFDC4216424FQ33726782-ADF13D39-94B8-46E8-A937-67523B547D4FQ33769117-41739C07-BE44-42B6-92E2-81DA2F447C3DQ33828409-2963BAC9-F955-4394-8AC4-3312DECC53C5Q33992604-4465AB28-073C-4397-8746-B7923457F169Q34449722-0DEF8F6D-366A-49D3-90D9-2250B2616394Q34550460-C1455445-A3BD-48E2-BB17-E59B75E8FA89Q34631703-C1FBFE0B-B872-4AA4-92C4-50C9819E810EQ34773458-8A626065-F538-4A76-BBB4-25B7A49ED5FBQ35033300-E23AAC7F-8CDD-486F-8E9C-98CCA642C5F6Q35043706-AB32C2DB-0C9F-443C-A998-AD864DD493B4Q35076221-C17907E3-CD83-4C88-BD90-071E6E2B42E5Q35125795-12EDCC9A-5D25-43C9-A2B1-929D28E3D147Q35337927-B858D807-9254-4D9C-B445-9B6E1304E35EQ35449387-BA25D943-D2A1-4C9B-9113-D502D664979CQ35500311-5CAA5B91-F619-4FEF-A6B3-52E9F7876531Q35908430-EC9F771F-4F00-4F27-8D7F-234C88E127C5Q35994416-2663AC56-AFBC-4F33-A305-758A30D964BFQ35999467-C8D94136-411E-4514-A0A2-894589026ACBQ36406541-0795A55D-07BB-44A2-B33E-E0483DF2EB78Q36545226-045E2A58-1B1A-4F5A-81C5-11D48703FAE1Q36605522-94728476-692D-4EC6-9E44-7D2B25D546D2Q36660669-2A08D784-05FF-4C97-89B9-1DDF471005D7Q36687288-CF273EBC-8BA1-48DC-834B-C01944D26DFAQ36741917-66DB8D86-78E0-4DAB-AE53-7131EC5B26B4Q36775204-C24269BE-0BC8-47BF-B99B-FB7AA1ADB305Q36834883-097BBE3D-93C8-491F-803A-1826E81043F4Q36887721-04C30BCA-73C9-4DF1-A127-0D97FA7C3EB0
P2860
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@ast
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@en
type
label
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@ast
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@en
prefLabel
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@ast
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@en
P2093
P2860
P4510
P356
P1433
P1476
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
@en
P2093
D J Kwiatkowski
E Lifshits
J A Engelman
J G Christensen
K Yonesaka
K Zejnullahu
P2860
P2888
P304
P356
10.1038/ONC.2009.526
P407
P577
2010-02-01T00:00:00Z
P5875
P6179
1008125644